Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer
Authors:
Open Access
- 1 July 2022
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 172, 221-230
Abstract
No abstract availableKeywords
Funding Information
- Fondation ARC pour la Recherche sur le Cancer (20191209484)
This publication has 28 references indexed in Scilit:
- CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon CancerNew England Journal of Medicine, 2016
- Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trialDigestive and Liver Disease, 2015
- Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant ChemotherapyJournal of Clinical Oncology, 2013
- The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibodyDiagnostic Pathology, 2012
- Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumorLaboratory Investigation, 2011
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal CancerJournal of Clinical Oncology, 2011
- Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon CarcinomaGastroenterology, 2009
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Cloning and chromosome assignment of the human CDX2 geneAnnals of Human Genetics, 1997
- A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samplesHuman Pathology, 1995